Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?

Niels Willem Boone
Roelof Wouter Frederik van Leeuwen
Maastricht University Medical Centre, Department of Clinical Pharmacy and Toxicology, Maastricht, The Netherlands

Recently our hospital pharmacy, which serves an academic hospital with an internationally well-known department of ophthalmology, received a request for the aseptic preparation of an alteplase syringe solution for subretinal administration. Looking for dose rationale, our ophthalmology doctor came up with a concentration based on an article published by Arias and colleagues in *Clinical Ophthalmology* in 2010.\(^1\) This article is on subretinal alteplase administration for hemorrhagic age-related macular degeneration. In the methods section, a concentration of 125 mg/mL alteplase was declared, which we found peculiar. This concentration cannot be acquired with the commercially available preparation (which has a maximum concentration of 2 mg/mL), and could lead to undesirable side effects. In the literature, it is stated that an alteplase dose should be in the range of 200 µg/mL.\(^2\) Did the authors mean 125 µg/mL?

**Disclosure**

The authors declare no conflicts of interest in this work.

**References**
